Search Result

Results for "

Naphthyridin-Me-dimethoxybenzene-COOH

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) CXCR (4) Epigenetic Reader Domain (1) ERK (1) GHSR (1) GnRH Receptor (2) Histone Demethylase (1) HIV (1) Ligands for Target Protein for PROTAC (1) Notch (1) Opioid Receptor (1) PROTACs (1) Somatostatin Receptor (1) Urotensin Receptor (1)
By Research Areas:	Cancer (8) Cardiovascular Disease (1) Endocrinology (5) Infection (1) Neurological Disease (3)

Inhibitors & Agonists

Peptides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1170

N-terminally acetylated Leu-enkephalin Ac-L-Tyr-Gly-Gly-L-Phe-D-Leu-COOH	Opioid Receptor	Neurological Disease
N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-P0009A

Cetrorelix Acetate 1 Publications Verification SB-75 acetate	GnRH Receptor	Neurological Disease Endocrinology
Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC₅₀ of 1.21 nM .

HY-159596

**Naphthyridin-Me-dimethoxybenzene-COOH**	Ligands for Target Protein for PROTAC	Cancer
Naphthyridin-Me-dimethoxybenzene-COOH is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). Naphthyridin-Me-dimethoxybenzene-COOH can be used in synthesis CW-3308 (HY-159579) .

HY-159579

CW-3308	PROTACs Epigenetic Reader Domain	Cancer
CW-3308 is an orally effective PROTAC that selectively targets BRD9 and is expected to be used to inhibit synovial sarcoma, rhabdomyoma, and other BRD9-dependent human diseases. CW-3308 is composed of PROTAC target protein ligand Naphthyridin-Me-dimethoxybenzene-COOH (HY-159596) (red part), Linker 3-Azaspiro[5.5]undecane-9-methanol (HY-159598) (black part), E3 ubiquitin ligase ligand Thalidomide-methylpyrrolidine (HY-159597) (blue part), where the conjugate of E3 ubiquitin ligase ligand + linker is Thalidomide-pyrrolidine-C-azaspiro (HY-159599) ^{[1] ^.}

HY-P1985A

Notch 1 TFA	Notch	Cardiovascular Disease Cancer
Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .

HY-P10973

Peptide R analogue 10	CXCR ERK	Cancer
Peptide R analogue 10 (compound 10) is an analog of the CXCR4 antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P5568

Siamycin III RP 71955	HIV	Infection
RP 71955 is an antimicrobial peptide against HIV-1 .

HY-P0009B

Cetrorelix diacetate SB-75 diacetate	GnRH Receptor	Neurological Disease Endocrinology
Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC₅₀ of 1.21 nM .

HY-P10819

S9-CMC1 TFA	Histone Demethylase Apoptosis	Cancer
S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .

HY-P10964

Tezusomant	GHSR	Endocrinology
Tezusomant is a growth hormone receptor antagonist. Tezusomant is promising for research of diseases such as acromegaly caused by excessive growth hormone secretion .

HY-P0171

Motixafortide 3 Publications Verification BKT140 (4-fluorobenzoyl); BL-8040; TF14016	CXCR	Endocrinology Cancer
Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC₅₀ vakue of ～1 nM.

HY-P4452

PRL 2915	Somatostatin Receptor Urotensin Receptor	Endocrinology
PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM .

Cat. No.	Product Name	Target	Research Area

HY-P1170

N-terminally acetylated Leu-enkephalin Ac-L-Tyr-Gly-Gly-L-Phe-D-Leu-COOH	Opioid Receptor	Neurological Disease
N-terminally acetylated Leu-enkephalin is the N-terminally acetylated form of Leu-enkephalin. Leu-enkephalin is a five amino acid endogenous peptide that acts as an agonist at opioid receptors.

HY-P0009A

Cetrorelix Acetate 1 Publications Verification SB-75 acetate	GnRH Receptor	Neurological Disease Endocrinology
Cetrorelix Acetate (SB-75 acetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC₅₀ of 1.21 nM .

HY-P1985A

Notch 1 TFA	Notch	Cardiovascular Disease Cancer
Notch 1 TFA (Notch homolog 1, translocation-associated) can encode a member of the NOTCH family of proteins. Members of this Type I transmembrane protein family share structural characteristics including an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple different domain types .

HY-P10973

Peptide R analogue 10	CXCR ERK	Cancer
Peptide R analogue 10 (compound 10) is an analog of the CXCR4 antagonist peptide Peptide R (HY-P4111) with stronger antagonistic potency, specificity and plasma stability. Peptide R analogue 10 can inhibit CXCL12-mediated cell migration, ERK phosphorylation and CXCR4 internalization. Peptide R analogue 10 can be used in the study of CXCR4 overexpressing leukemia and colon cancer .

HY-P11011

Peptide R54 Pep R54; CXCR4 antagonist peptide 19	CXCR	Cancer
Peptide R54 (Pep R54; CXCR4 antagonist peptide 19) is an antagonistic peptide targeting CXCR4 with significant anticancer activity. Peptide R54 inhibits CXCR4-dependent cell migration, epithelial-mesenchymal transition, and lung metastasis development, with better serum stability and higher CXCR4 affinity than the lead compound (IC₅₀=20 nM). Peptide R54 synergizes with anti-PD-1 therapy to exert anti-tumor activity in vivo, enhances granzyme activity, and reduces infiltration of Foxp3 cells. Peptide R54 can be used in the study of colon cancer, ovarian cancer, and melanoma .

HY-P5568

Siamycin III RP 71955	HIV	Infection
RP 71955 is an antimicrobial peptide against HIV-1 .

HY-P0009B

Cetrorelix diacetate SB-75 diacetate	GnRH Receptor	Neurological Disease Endocrinology
Cetrorelix diacetate (SB-075 diacetate) is a potent gonadotropin-releasing hormone (GnRH) receptor antagonist with an IC₅₀ of 1.21 nM .

HY-P10819

S9-CMC1 TFA	Histone Demethylase Apoptosis	Cancer
S9-CMC1 TFA is a covalent peptide lysine-specific demethylase 1 (LSD1) inhibitor with an IC₅₀ value of 2.53 μM. S9-CMC1 TFA specifically recognizes Cys360 in the enzyme-active region. S9-CMC1 TFA inhibits LSD1 activity, increasing H3K4me1 and H3K4me2 levels, leading to G1 cell cycle arrest and apoptosis and inhibiting cell proliferation. S9-CMC1 TFA significantly inhibits tumor growth in A549 xenograft animal models .

HY-131374

TN14003	CXCR	Cancer
TN14003 is a CXCR4 inhibitor. TN14003 has antitumor activity .

HY-P10964

Tezusomant	GHSR	Endocrinology
Tezusomant is a growth hormone receptor antagonist. Tezusomant is promising for research of diseases such as acromegaly caused by excessive growth hormone secretion .

HY-P0171

Motixafortide 3 Publications Verification BKT140 (4-fluorobenzoyl); BL-8040; TF14016	CXCR	Endocrinology Cancer
Motixafortide (BKT140 4-fluorobenzoyl) is a novel CXCR4 antagonist with an IC₅₀ vakue of ～1 nM.

HY-P4452

PRL 2915	Somatostatin Receptor Urotensin Receptor	Endocrinology
PRL 2915 is a potent human somatostatin subtype 2 receptor (hsst₂) antagonist with a K_i of 12 nM .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.